In a welcome move, Natera saw its Relative Strength Rating rise from 69 to 72 on Wednesday.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their largest climbs. See if Natera can continue to show renewed price strength and clear that threshold.
Natera is building a consolidation with a 183.00 entry. See if it can clear the breakout price in heavy volume. Keep in mind that it's a later-stage consolidation, and those are riskier than earlier-stage patterns.
The company showed 0% EPS growth last quarter. Sales increased 32%.
Natera earns the No. 17 rank among its peers in the Medical-Services industry group. GeneDx Holdings, Hims & Hers Health and Sotera Health are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
